PRESENTATION

Q2 2020 — Presentation

Q2 2020PDF · 19 pages611 KB
Merck
Q2 2020 Earnings

-- 1 of 19 --

Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
2
This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe
harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include statements with
respect to the company's plans to spinoff certain of its businesses into an independent company, the timing and structure of such spinoff, the
characteristics of the business to be separated, the expected benefits of the spin-off to the company and the expected effect on the company's
dividends. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant
risks and uncertainties. There can be no guarantees with respect to whether the proposed spinoff will be completed on the proposed timetable or at
all or with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth
in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

-- 2 of 19 --

$10.9B
-5%
Q2 performance highlights
3
Advanced
the
pipeline
1. Growth rates exclude impact of foreign exchange
2. The GAAP to non-GAAP reconciliation is available in the Supplemental Tables to Merck’s Q2 2020 earnings release.
3. GAAP EPS $1.18
Revenue
impacted by
reduced
patient
access 1
• 	Continued commitment to value-enhancing
business development, including three COVID-19
research deals and the Animal Health acquisitions of
Sentinel and Quantified Ag
• 	Returned $1.6 billion to shareholders through
dividends
• 	Continued to invest in our key growth pillars and
made significant progress in advancing our pipeline
$1.37
+9%
Strong
financial
discipline
helped drive
non-GAAP
EPS growth 1
• 	In the U.S., received 7 FDA approvals across oncology
portfolio, including 4 for KEYTRUDA (KN-177,
KN-629, TMB-H, Q6W dosing), 2 for Lynparza (PAOLA-1,
PROfound) and 1 for Koselugo (NF-1)
• 	Outside the U.S., Lynparza approved by EMA for pancreatic
cancer based on POLO, and KEYTRUDA approved in China
for esophageal cancer based on KN-181
• 	Virtually presented first-time and updated data from
oncology program at AACR and ASCO, including KN-177,
KN-189, KN-204, KN-355, KN-524, KN-555, KN-799,
and MK-6482 in VHL
• 	GARDASIL 9 granted accelerated approval by FDA for HPV-
related H&N cancers, and first 2 positive Phase 3 datasets for
investigational PCV vaccine, V114, were presented at ISPPD
• 	FDA approved RECARBRIO for HABP/VABP and data from
STEGLATRO’s VERTIS CV trial were presented at ADA
Created
shareholder
value

-- 3 of 19 --

Fundamentals of the business remain intact through
the first half of the year
4
Growth in 1H20
reflects strong
underlying demand
for our innovative
portfolio
+4%
Total Revenue
+12%
Animal Health
+3%
Human Health
1. Growth rates reflect year-to-date (1H20 vs. 1H19) and exclude the impact of foreign exchange.

-- 4 of 19 --

Oncology: strong growth across portfolio
• 	KEYTRUDA sales of $3.4B increased 31% year-
over-year, reflecting strong growth despite
slight decline in new patient starts due to
COVID-19
o 	In the U.S sales of $2.0B driven by growth
across all key tumor types, including
continued growth in lung
o 	23% international growth, driven by global
uptake in lung more
• 	Strong growth from both Lynparza and Lenvima
continues to bolster oncology portfolio with
growth of 62% and 57%, respectively
• 	Year-to-date growth across our oncology
business continues to reflect fundamental
strength with KEYTRUDA, Lynparza and
Lenvima growing 38%, 72% and 64%,
respectively
1. All growth rates exclude the impact of foreign exchange. 	5
2Q19 	2Q20
+31% YOY
KEYTRUDA Performance
2Q19 	2Q20
Lynparza Performance
+62% YOY
2Q19 	2Q20
Lenvima Performance
+57% YOY

-- 5 of 19 --

2Q19 	2Q20
Vaccines: short-term challenges driven by stay-at-home orders
• 	Vaccines sales declined 29% year-over-year due
to COVID-19 related stay at home orders and
reduced patient visits to physician offices
• 	GARDASIL sales of ~$660M decreased 24%
year-over-year
o 	In the U.S., sales decreased 63% primarily due
to reduced patient access to providers
o 	Ex-U.S., GARDASIL sales grew 18%, reflecting
underlying demand growth in China, partially
offset by lower demand in Hong Kong due to
the pandemic
• 	Pediatric vaccines also declined due to lower
demand in the U.S. related to the COVID-19
pandemic and fewer measles outbreaks
• 	Year-to-date, demand drove 4% global growth
for GARDASIL
1. All growth rates exclude the impact of foreign exchange. 	6
-24% YOY
GARDASIL Performance

-- 6 of 19 --

Hospital: reduced access to hospitals & delayed procedures
2Q19 	2Q20
• 	BRIDION sales of ~$225M declined 18%
year-over-year driven by delayed or
canceled surgery procedures
o 	Underlying health of business remains
strong, and year-to-date BRIDION
sales were flat year-over-year
• 	Ongoing launch of PREVYMIS drove 67%
growth in the quarter
• 	Demonstrated commitment to the
development of novel antibiotics and
antivirals as evidenced by recent
RECARBIO HABP/VABP approval
1. All growth rates exclude the impact of foreign exchange.
-18% YOY
7
BRIDION Performance

-- 7 of 19 --

Animal Health: underlying strength more than offset COVID-19 headwind
2Q19 	2Q20
• 	Animal Health sales increased 3% to ~$1.1B,
absorbing ~$100M COVID-19 headwind
o 	Livestock sales increased 3% due to an
acquisition in Animal Health Intelligence.
Sales were impacted by decreased
protein and milk demand due to
restaurant and school closures resulting
from the pandemic
o 	Companion Animal sales increased 3%,
driven by strong growth from the
BRAVECTO line of products. Sales
reflected reduced veterinary visits
• 	Year-to-date, Animal Health increased
12%, reflecting the fundamental strength
of the business and an acquisition
1. All growth rates exclude the impact of foreign exchange.
+3% YOY
8
Animal Health Performance

-- 8 of 19 --

Human health performance impacted by global pandemic
United
States
Canada
Europe 2
Latin
America
Eastern Europe /
Middle East
Africa
Japan
+13%
China
Global
pharmaceutical
sales -6%1
$343M
-2%
+14% 	-8%
-8%
-11%
-8%
Asia Pacific
-5%
9
1. All growth rates exclude the impact of foreign exchange.
2. Europe primarily represents all European Union countries and the European Union accession markets.

-- 9 of 19 --

Q2 2020 financial results summary:
Strong P&L resiliency despite patient access challenges
Q2 2020 	Q2 2019 	Change Change
Ex-FX
Sales 	$10.9B 	$11.8 	-8% 	-5%
GAAP Gross Margin 	70.9% 	71.1% 	-0% 	-0%
Non-GAAP Gross Margin 2 	73.8% 	75.4% 	-2% 	-2%
GAAP net income 1 	$3.0 	$2.7 	+12% 	+17%
Non-GAAP net income
that excludes certain items 1,2 	$3.5 	$3.4 	+4% 	+7%
GAAP EPS 	$1.18 	$1.03 	+15% 	+19%
Non-GAAP EPS that excludes
certain items 2 	$1.37 	$1.30 	+6% 	+9%
$ in billions, except EPS amounts
10
1. Net income attributable to Merck & Co., Inc.
2. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.

-- 10 of 19 --

Confident in the long-term fundamental strength of our business
11
Business Recovery 	Financial Strength 	Pipeline Progress 	Strategic Direction
• 	Business recovered
through the quarter with
stronger underlying
performance and
improving momentum
into quarter-end
• 	Key growth drivers remain
intact with strength in the
quarter from KEYTRUDA
and Animal Health and
favorable recovery trends
in both Vaccines and
Hospital
• 	Financial strength and
conservatively positioned
balance sheet allow for
continued execution on
capital allocation priorities,
including business
development
• 	Disciplined expense
management expected to
result in operating
leverage
• 	Pipeline continues to
mature with key upcoming
presentations, data
readouts and filings across
late-stage pipeline assets,
including gefapixant, V114,
vericiguat, islatravir, and
in early stage oncology
• 	Accelerating our COVID-
19 research efforts
• 	Committed to the spinoff
of Organon & Co. to best
position both companies
for stronger futures
• 	Evolving the operating
model to help ensure
success in a changing
landscape
• 	Remain highly focused on
strategic business
development

-- 11 of 19 --

Leveraging strong legacy and expertise in vaccines and anti-infectives
to thoughtfully select and develop promising SARS-CoV-2 candidates
12
Conviction: Vaccine development based on
technology and platforms proven to work
safely and effectively
Effectiveness: Vaccines that we believe
could be effective with a single dose
Scalability: Investigational vaccines that
can be deployed globally
Vaccines 	Antivirals
Timeliness: Opportunity to have a more
immediate and direct impact on SARS-CoV-2
outbreak
Formulation: Focus on oral formulation with
potential to provide convenience in access
and administration
Applicability: Agent with the possibility to
play a role in this and potential future
coronavirus outbreaks

-- 12 of 19 --

Driving multiple scientific programs in an effort to help combat COVID-19
13
Vaccine candidates 	Antiviral candidate
IAVI Collaboration
(V590)
Themis Acquisition
(V591)
Ridgeback Collaboration
(MK-4482)
Collaboration with IAVI to develop an
investigational vaccine against SARS-
CoV-2 using the recombinant vesicular
stomatitis virus (rVSV) technology
rVSV is the basis for Merck’s Ebola
Zaire virus vaccine, ERVEBO, which is
the first rVSV vaccine approved for use
in humans
V590 expected to enter the clinic in the
second half of 2020
Acquisition of Themis, a company
focused on vaccines and immune-
modulation therapies for infectious
diseases and cancer
Broad pipeline of vaccine candidates
and immune-modulatory therapies
developed using Themis’ innovative
measles virus vector platform
V591 expected to enter the clinic in
3Q20
Collaboration with Ridgeback Bio to
develop MK-4482, an orally available
antiviral candidate for the treatment of
patients with COVID-19
To date, initial results from a Phase 1
study suggest compound is well
tolerated
Phase 2 trials currently underway

-- 13 of 19 --

Updated guidance assumptions: COVID-19
14
Pandemic Recovery Assumptions
• 	Favorable recovery trends through the end of the second quarter:
o 	Height of pandemic impact seen in April; recovery began in May and improved through June
• 	Improved patient access to hospitals and other healthcare sites
• 	Healthcare system is better positioned to provide care to patients as we move through the balance of the year
• 	Continue to anticipate a gradual recovery through the third quarter with a return to normal operating levels in the fourth quarter
Human Health 	Animal Health
• 	Meaningful increases in wellness visits through end of
quarter set up favorable trends heading into the second
half of the year
• 	We will continue to monitor patient access to providers
given ongoing pandemic, but believe healthcare system
overall is adapting in order to provide care to patients
• 	Improving trends favorably impact full year outlook across
companion animal and livestock businesses following vet clinic
openings and lifting of stay at home orders
• 	We will continue to monitor restaurant and school openings
and potential impact on demand for our livestock products

-- 14 of 19 --

Updated full-year 2020 guidance
1. GAAP Gross Margin Rate: Higher than 2019
2. GAAP Operating Expenses: Lower than 2019 by a low-single-digit rate
3. GAAP Tax Rate: ~15.0 – 15.5%
4 The GAAP to non-GAAP reconciliation is available in Merck’s Q2 2020 earnings release
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $46.1B - $48.1B
-2% to +3% (+1% to +5% ex-FX)
$47.2 - $48.7B
+1 to +4% (+3% to +6% ex-FX)
• 	Assumes ~2.0% negative FX impact
• 	Reflects strong underlying performance
and reduced COVID-19 impacts
Non-GAAP
Gross Margin Rate 1 	~75.0% 	~75.0% 	• 	No change
Non-GAAP
Operating Expenses2 	Low single-digit rate decrease 	Roughly flat • 	Increased spend on COVID-19 research
efforts
Other (Income) / Expense 	~$200M of other expense 	~$550M of other income • 	Reflects gains on equity investments,
based on 6/30/20 prices
Tax Rate 3 	17.0% to 18.0% 	16.0% to 16.5% • 	Reflects favorable impact of earnings
mix
Shares Outstanding 	~2.54B 	~2.54B 	• 	No change
GAAP EPS4 	$4.14 to $4.29 	$4.58 to $4.73
Non-GAAP EPS 4 	$5.17 to $5.37
0% to +4% (+3% to +7% ex-FX)
$5.63 to $5.78
+8% to +11% (+11% to +14% ex-FX) • 	Assumes ~3% negative FX impact
15

-- 15 of 19 --

Balanced approach to capital allocation:
Investing in the business and creating value for shareholders
Capital Investments
2019 to 2023
~$ 20.0B
Over 5 years, including expanding manufacturing
capacity for Oncology, Vaccines, and Animal
Health. Includes >$10.0B in the U.S.
Over the Past 12 Months
$0
$1
$2
$3
$4
$5
$6
$7
$8
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development -
Ex Divestitures
Share
Repurchase (net
of Options
Proceeds)
$7.4 $3.8
$5.9 	$5.8
$3.6	
Billions
ORDER OF
PRIORITY
Commitment to the Dividend
$1.72 	$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$1.40
$1.70
$2.00
$2.30
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020E
Dollars per share
+11% 	+2% 	+2% +2% 	+2% +2%
+11%
16
+15%
• 	$8.9 billion invested in R&D ($7.4 billion after-tax)
• 	~$6 billion spent on business development, including
acquisitions and collaborations for 3 COVID-19 vaccine and
antiviral candidates, and 2 Animal Health deals
• 	$10 billion in dividend and share repurchases
o 	Remain committed to the dividend, which increased
11% in 2020
o 	Returned $3.7 billion share repurchases (excluding
option proceeds)
• 	Issued $4.5B of debt at low rates
Balanced Capital Allocation to Return Cash to Shareholders
While Investing in Growth Over Past 12 Months

-- 16 of 19 --

Continued progress on the spinoff of Organon & Co.
17
Announced Jersey City, NJ as the global
headquarters for Organon & Co.
Appointment of key external talent to add to
strong executive leadership team:
o 	Matt Walsh, Chief Financial Officer
o 	Rachel Stahler, Chief Information Officer
o 	Deborah H. Telman, General Counsel
Spinoff remains on track for completion in the
first half of 2021
Rooted in our belief that
two, more focused
companies will drive
stronger growth and
unlock long-term value for
patients and shareholders

-- 17 of 19 --

Creating long-term value for patients, employees and shareholders
Anchored by our deep bench of talent
and commitment to our mission
Next 5 Years
Strong execution driving
sustainable revenue growth,
meaningful margin expansion and
accelerated bottom-line growth
5-10 Years
Rich pipeline addressing
areas of high unmet need to
drive performance over the
next 5 to 10 years
10+ Years
Revitalized discovery efforts and
increased expertise in biology to
deliver ongoing scientific
breakthroughs for decades to come
18

-- 18 of 19 --

Continuing to make progress on our ESG commitments
Access to
Health
Employees
Environmental
Sustainability
Ethics and
Transparency
Earning trust and confidence of stakeholders is critical for a company in the business of marketing and selling
medicines and vaccines
• 	Demonstrated commitment to transparency through disclosures about our business and how we operate, including being first
pharmaceutical company to publish a multi-year report about pricing practices
• 	Work with broad range of stakeholders to help develop and advance innovative financing and payment models to improve access
• 	Integrating the SDGs into our reporting to demonstrate our commitment to sustainable development
Executing an environmental sustainability strategy to take advantage of opportunities to reduce environmental impact
across operations and supply chain
• 	Featuring energy-conservation and water-use-reduction initiatives
• 	Reducing environmental impacts as evidenced by an EPA Green Chemistry Challenge Award four years running (seven awards overall)
• 	Purchasing electricity from renewable energy sources to reduce greenhouse gas emissions, including the launch of our first large wind virtual
power purchase agreement
• 	Collaborating with suppliers and customers to address shared needs and interests in environmentally beneficial ways
Fostering diverse and gender-balanced workforce essential to performance as a research-intensive company and to attracting most
talented scientists
• 	Offering numerous programs to engage employees and promote positive work environment (including female mentorship by female Board members)
• 	Partnering with Year Up, a nonprofit that enables low-income young adults of color to move from minimum wage to meaningful careers in just one year
• 	Increase in 2019 in women on our Board (25%), in executive roles (36%), and in management roles (43%)
• 	Recognized as a 2020 best place to work for LGBTQ equality by the Human Rights Campaign (HRC) Foundation
• 	Identified by the American Indian Science and Engineering Society (AISES) as a 50 Top STEM Workplaces for Indigenous STEM Professionals
Increasing access to health to advance Merck’s efforts to serve more patients
• 	Rich history of making medicines and vaccines accessible and affordable through responsible pricing practices and industry-leading patient support programs
• 	Implemented refreshed Access to Health Guiding Principles to ensure we continue to fulfill our commitment to access by focusing on the most critical issues
• 	Reaching more than 11 million women worldwide through Merck for Mothers, a $500 million initiative
• 	Through our 30+ year old MECTIZAN® Donation Program, eliminated river blindness in 4 Latin American countries and in parts of 6 African countries so far, and
eliminated lymphatic filariasis in 2 countries in Africa and the Middle East
• 	Thanks to the commitment of many collaborators across multiple sectors, ERVEBO, Merck’s vaccine for the prevention of disease caused by Zaire ebolavirus, is now
approved in the United States, conditionally approved in the European Union, prequalified by the WHO, and registered in six African countries (with additional
African registrations pending review)
19

-- 19 of 19 --